by sfrazee | Dec 23, 2022 | White Papers
This Policy Brief analyzes the impact of The Inflation Reduction Act (IRA) on generic and biosimilar competition. We first review the large savings that generic and biosimilar competition entails in the U.S., which is threatened by competitors’ uncertain investments....
by jmanor | Nov 29, 2022 | White Papers
Despite the large disease burden imposed by Alzheimer’s disease (AD), little quantitative evidence exists on the aggregate value stemming from innovation slowing the progression of the disease. To fill this gap, this paper uses the existing evidence base to assess the...
by sfrazee | Nov 1, 2022 | Uncategorized, White Papers
This policy brief contains a set of recommendations for improving access and competition in the state of Wisconsin’s health care system. These recommendations are based on how current state and federal reforms apply to Wisconsin. The brief is focused on four main...
by sfrazee | Oct 26, 2022 | White Papers
This paper assesses the value of take-home Alzheimer’s dementia (AD) treatments over physician-administered ones. We find that shifting from a physician-administered treatment to a home-based one in the US would generate a value of $4.67 billion to $25.51 billion...
by jmanor | Aug 12, 2022 | White Papers
A longstanding economic literature argues that the total welfare loss of a disease comes not only from the direct effects of the disease itself, but also the costs of preventing the disease. This paper assesses how new medical innovations for COVID-19—specifically...
by jmanor | Aug 11, 2022 | White Papers
From April 2020 through at least the end of 2021, Americans died from non-Covid causes at an average annual rate 97,000 in excess of previous trends. Hypertension and heart disease deaths combined were elevated 32,000. Diabetes or obesity, drug-induced causes, and...
